BioXcel Therapeutics is trading 13% up at $0.15, primarily as biotech stocks gain while investors also trade the company’s restructuring situation.
- The stock is rebounding after three consecutive sessions of steep losses.
- BioXcel filed Chapter 11 on August 27, 2026, secured up to $19 million in new-money debtor-in-possession financing, and entered a proposed $57.5 million Teva asset-sale agreement plus potential milestones.
- Those developments remain important sources of volatility but do not clearly explain today’s upside.